Breast Cancer Now media statements
We respond to NHS Breast Screening Programme Statistics for Scotland 2017/18 to 2019/20
Mia Rosenblatt, Associate Director of Evidence, Policy and Influencing at Breast Cancer Now, said:
We respond to NHS England breast cancer waiting times: March 2021
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to the Clinical Radiology UK Workforce Census 2020 Report from The Royal College of Radiologists
The Royal College of Radiologists' (RCR) latest Clinical Radiology UK Workforce Census 2020 Report reveals the significant challenges facing...
We welcome the approval of trastuzumab deruxtecan for use on the Cancer Drugs Fund
The National Institute for Health and Care Excellence (NICE) has today - 20 April 2021 - announced its decision to recommend breast cancer d...
We respond to NHS England breast cancer waiting times: February 2021
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now said:
We welcome introduction of new treatment method for HER2 positive breast cancer by NHS England
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to new study into early-stage breast cancer treatment in UK during initial months of COVID-19 pandemic
Responding to a new study into the treatment of early breast cancer in the UK, between March and May 2020, led by the University of Manchest...
We respond to a new study about lifestyle and breast cancer risk
A new study funded by the World Cancer Research Fund (WCRF) examined people’s exposure to modifiable risk factors using data from the Health...
We respond to NHS England breast cancer waiting times: January 2021
NHS England cancer waiting times data from January 2021, published on Thursday 11 March 2021, shows:
We respond to a study from King's College London into the effectiveness of the Pfizer COVID-19 vaccine for people with cancer
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
We welcome NICE approval of ribociclib with fulvestrant for use on the NHS
The National Institute for Health and Care Excellence (NICE) has today announced its decision to approve ribociclib with fulvestrant for rou...
We respond to draft NICE decision not to recommend abemaciclib with fulvestrant for routine use on the NHS
The National Institute for Health and Care Excellence (NICE) has today announced its decision to provisionally not recommend breast cancer t...